Clifford Samuel

WORK HISTORY

EDUCATION

SKILLS

ABOUT CLIFFORD SAMUEL

Advisor to Large Caps, Start-Ups, and NGOs on Issues Surrounding the Access and Distribution of Life-Saving Medicines in Emerging Markets and Low- and Middle-Income Countries. Clifford Samuel offers 30+ years of commercial leadership experience in the biopharmaceutical industry, including more than two decades of leadership at Gilead Sciences. As Principal at PCMS1 Consulting, he brings his sales, managed markets, and global commercial operations experience to companies needing consulting on biopharma investment opportunities, early stage clinical studies, and go-to-market strategies in emerging markets and resource-limited countries. Having built multiple global strategic partnerships, including collaborations with governments, non-governmental organizations, and generic drug manufacturers, Clifford is able to facilitate the delivery of critical medicines internationally in very complex/opaque markets. IMPACT @ GILEAD SCIENCESFrom 2007 to 2020, Clifford served at Gilead Sciences, culminating with SVP, Global Patient Solutions, with responsibility for more than 140 countries. His successful initiatives drove both access to medicines and ROI in geographies spanning Latin America and the Caribbean, Africa, South/Southeast Asia Pacific, and Eastern Europe. Leveraging a deep knowledge of the regulatory landscape and distribution network across the globe, Clifford spearheaded Gilead’s entry into generic licensing agreements with companies in Pakistan, India, and South Africa that created a competitive market for generic HIV and hepatitis B&C medicines, and most recently, Remdesivir to treat COVID-19. His efforts have resulted in the provision of medicines to more than 19 million people living with HIV/AIDS in these resource-limited countries.ONGOING LEADERSHIP CONTRIBUTIONSIn 2022, Clifford was granted a fellowship at the Berkman Klein Center for Internet & Society at Harvard University to explore voluntary licensing and access to medicines in the context of pandemics and health emergencies. He sits on the Board of Antiva Biosciences and the MTV Staying Alive Foundation. He is also the recipient of an Edward F. Weston Medal for Professional Achievement and was inducted into the National Academy of Engineering in 2019-“’ ℎ.” – presented at Business Council for International Understanding (BCIU)Clifford Samuel cliffordsamuel415(at)gmail.com +14•••••••07